Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences. Under this arrangement, Optime Care will serve as the exclusive specialty pharmacy provider for dispensing the newly FDA-approved and relaunched Vecamyl 2.5 mg tablets to patients. Tilde, a pharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, selected Optime Care for its proven track record in program continuity, prior experience with Vecamyl and Daraprim and expertise in managing small, specialized patient populations.
Health Technology Insights: RyboDyn Joins Lilly Gateway Labs to Advance Immunotherapies
“Our continued and expanded relationship with Tilde demonstrates their confidence in Optime Care’s ability to meet the needs of specialty patient populations through highly-personalized programs, tailored patient communications and educational support throughout the treatment journey,” says Bill Bertetto, general manager, Optime Care. “Tilde values the expertise of our dedicated Patient Care Teams who have a deep understanding of complex disease states and provide guidance every step of the way. These specialists help enhance patient access to essential therapies, streamline care coordination and ensure financial assistance is available to those in need.”
Leveraging innovative, proprietary technology platforms and patient engagement tools, Optime Care’s expert teams, including specially trained Patient Care Coordinators, deliver end-to-end solutions that drive improved individual outcomes and exceptional compliance rates.
Health Technology Insights: Smart Meter Warns Against Sending RPM Data to China
Akeel Mithani, president of Tilde states, “Optime Care is a trusted partner, reliably ensuring that patients with rare, complex diseases receive their medications on time and wherever needed. Over a year ago, we made a great decision to partner with Optime Care and we continue to rely on their unmatched expertise. Their teams consistently demonstrate a shared commitment to care for vulnerable specialty patients. It has been a gratifying experience working with Optime Care and we look forward to further collaboration to improve the clinical outcomes and quality of life for the patients we serve.”
Vecamyl (mecamylamine) had been unavailable for new patients following its acquisition from the previous owner. The Company has since partnered with new supply chain providers to address and resolve the prior supply challenges. The Company is pleased to announce that Vecamyl is now available through Tilde’s comprehensive patient support program, Tilde Total Care. Questions pertaining to access and affordability of Vecamyl (mecamylamine) should be directed to 1-877-794-0008.
Health Technology Insights: Ipsen Gets CHMP Nod for Cabometyx in Neuroendocrine Tumors
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
